Advertisement

Topics

Dementia Associated With Alzheimer's DiseaseGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Updated: 30052017] Prices from USD $1700

18:00 EDT 19 Jun 2017 | BioPortfolio Reports

DelveInsight's Report, Dementia Associated With Alzheimer's DiseaseGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Dementia Associated With Alzheimer's Disease Report is to understand the market and pipeline status of the drugs around the Dementia Associated With Alzheimer's Disease to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight's Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Dementia Associated With Alzheimer's Disease. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight's report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 4872 Hours to complete the process and ensure it is as uptodate as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE:
A snapshot of the global Market and Phase III therapeutics scenario for Dementia Associated With Alzheimer's Disease.
A review of the marketed products under prescription for Dementia Associated With Alzheimer's Disease, regulatory information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
Product profiles for marketed products for Dementia Associated With Alzheimer's Disease with complete description of mechanism of action, therapeutic class, target, routes of administration and chemical details.
Coverage of API Manufacturers for Dementia Associated With Alzheimer's Disease drugs in the United States, Europe and Asian Regions with location details.
Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Dementia Associated With Alzheimer's Disease drugs.
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Dementia Associated With Alzheimer's Disease drugs.
Coverage of Dementia Associated With Alzheimer's Disease Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research development progress.
Coverage of the United States Drug Master File US DMF available for Phase III Pipeline Drugs.
Key discontinued Marketed products.
Global Sales Figure to 2018.
Reasons to buy
Evaluate the marketing status and exclusivity details of Dementia Associated With Alzheimer's Disease key products to exploit opportunities for generic drug development opportunities.
Identify and understand important and diverse types of therapeutics under Phase III development for Dementia Associated With Alzheimer's Disease.
Design effective counterstrategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Dementia Associated With Alzheimer's Disease.
API intelligence over marketed drugs forDementia Associated With Alzheimer's Diseaseand gaining primary intelligence over active ingredients manufacturers across the globe.
API intelligence over leading Phase III Pipeline drugs.
Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
Understanding the scope of the Phase III Drugs with nil regulatory filings.
Understanding the chemical route of synthesis of approved drugs for Dementia Associated With Alzheimer's Disease.
Uncovering opportunities in the rapidly growing US market.

Original Article: Dementia Associated With Alzheimer's DiseaseGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Updated: 30052017] Prices from USD $1700

NEXT ARTICLE

More From BioPortfolio on "Dementia Associated With Alzheimer's DiseaseGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Updated: 30052017] Prices from USD $1700"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Dementia
Dementia describes a range of symptoms of cognitive decline. For example memory loss, problems with reasoning and communication skills, and a reduction in a person's abilities and skills in carrying out daily activities. There are about 820,000 peo...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...